RCEL Earnings & Financial Statements
AVITA Medical, Inc.
$13.46
+$0.36(+2.71%)
51
Overall
40
Value
75
Tech
39
Quality
Market Cap
$405.14M
Volume
143.43K
52W Range
$3.22 - $13.71
Target Price
$12.33
RCEL earnings and financial statements: AVITA Medical, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RCEL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $71.61M | $64.25M | $50.14M | $34.42M | $29.23M |
| Cost of revenue | $12.79M | $9.09M | $7.78M | $6.04M | $5.95M |
| Operating income | -$42.53M | -$56.59M | -$42.66M | -$27.50M | -$26.54M |
| EBITDA | -$41.23M | -$55.30M | -$33.54M | -$26.05M | -$25.81M |
| Net income | -$48.59M | -$61.84M | -$35.38M | -$26.66M | -$26.58M |
| EPS (diluted) | $-1.74 | $-2.39 | $-27.93 | $-1.07 | $-1.17 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $56.39M | $79.71M | $111.64M | $98.26M | $125.50M |
| Total liabilities | $73.04M | $74.97M | $61.89M | $12.97M | $9.87M |
| Shareholders’ equity | -$16.65M | $4.50M | $49.06M | $84.74M | $115.66M |
| Cash and equivalents | $10.24M | $14.05M | $22.12M | $18.16M | $110.75M |
| Long-term debt | $2.13M | $45.09M | $41.51M | $306.0K | $878.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$31.20M | -$48.94M | -$38.01M | -$19.09M | -$25.86M |
| Capital expenditure | -$1.74M | -$9.33M | -$1.45M | -$525.0K | -$1.17M |
| Free cash flow | -$32.93M | -$58.27M | -$39.46M | -$19.61M | -$27.04M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RCEL | $13.46 | +2.7% | 143.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |